anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
The present invention relates to a kind of medicament for the treatment of vulvovaginal candidiasis, it is made up of the material of following weight portion: little contribution 10-20 part, Herba seu Radix Calanthes 5-15 part, Herba Sheareriae 10-20 part, mountain Pericarpium Citri Reticulatae Viride 10-20 part, Semen Iridis 1-10 part, Herba Dodartiae Orientalis 20-30 part, Herba sei Radix Crotalariae tetragonae 1-10 part, Scobis Diospyroris Ebeni 5-15 part, Camellia sinensis O. Ktze. Var. macrophylla Sieb. 10-20 part, father-in-law's ripple 1-10 part, Folium Viticis Negundo 20-30 part, snow medicine 10-20 part, nine pipe blood 5-15 parts, Fructus polygoni sieboldii 10-20 part, Herba Lespedezae Cuneatae 20-30 part, Physalis alkekengi L. var. francheti (Mast.) Makino 5-15 part, Herba Violae Hortensis 5-15 part, Herba Pentanematis Indici 20-30 part, Fructus Vaccinii Bracteati 5-15 part, Radix Glycyrrhizae 1-10 part.Pharmaceutical treatment vulvovaginal candidiasis of the present invention is evident in efficacy, and easy and simple to handle, use safety, toxic and side effects are few, clinical be easy to promote, patient be easy to accept.
CONTEXT: Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors with high heritability, justifying systematic genetic screening for a germline variant in one of the twenty predisposing genes described to date.
PURPOSE: To describe the experience of one endocrine oncogenetic laboratory over a period of 21 years (2001-2022), from the beginning of PPGL genotyping with Sanger sequencing in 2001 to the implementation of next-generation sequencing (NGS).
METHOD: The activity database of an academic oncogenetic laboratory was searched to extract patients/relatives identified with a pathogenic variant/likely pathogenic variant (PV/LPV) over a period of 21 years. Clinical and genetic data were compared.
RESULTS: In total, 606 index cases with PPGL and 444 relatives were genotyped. Genotyping of index cases was performed by Sanger sequencing and gene deletion analysis in 327 cases and by NGS in 279. Germline PV/LPV spanning 10 genes was identified in 165 index cases (27.2%). Several recurrent PV/LPVs in SDHx were observed in non-related index cases, the most frequent being SDHD, c.170-1G>T (n=28). This subgroup showed great phenotypic variability both between and within families in terms of both tumor location and number. Four patients (1.1%) with PV/LPV in SDHx had 3PA (Pituitary Adenoma and pheochromocytoma/paraganglioma) syndrome. 258 relatives (58.1%) had inherited a PV/LPV in one driver gene. The rate of PV/LPV carriers who were symptomatic at first imaging evaluation was 32%, but varied between<20% in SDHB and SDHC and >50% in SDHD, VHL and MAX.
CONCLUSION: Our experience confirmed previously established genotype-phenotype correlations, but also highlights atypical clinical presentations, even for the same genetic variant. These data must be taken into account for optimal patient follow-up and management.
PURPOSE:A pharmaceutical preparation for oral administration extremely improving biological absorption of macrolide antibiotic, obtained by blending the macrolide antibiotic with sodium polyacrylate in a specific ratio. CONSTITUTION:1pt.wt. macrolide antibiotic is blended with 0.01-15pts.wt., preferably 0.1-15pts.wt. sodium polyacrylate (PANA for short). Biological absorption of the macrolide antibiotic can be improved. For example, blood concentration of the macrolide antibiotic 1hr after administration is five times as much as that of tylosin. In the operation, PANA is designated as a food additive and a feed additive and has preferably about 4,000,000-5,000,000mol.wt. The amount of PANA is preferably 1-95W/W% based on the whole amount of the pharmaceutical preparation.
PURPOSE:To stick a poultice over a long time without imparting a feeling of physical disorder, by forming a protective layer based on a specific acrylate copolymer and a softening agent and having a specific thickness to the single surface of a sticking agent having stickiness to the wet surface of a mucous membrane. CONSTITUTION:A poultice for the mucous membrane of the oral cavity is constituted by forming a protective layer to the single surface of a sticking layer having stickiness to the wet surface of the mucous membrane. The protective layer is formed from an acrylate type (co)polymer containing alkyl (meth)acrylate as a (co)polymer component in a ratio of 40wt.% or more and a softening agent capable of softening said (co)polymer. This acrylate type (co)polymer is soluble in an alcoholic solvent and insoluble in water, and the softening agent has an ester bond and/or ether bond in the molecule thereof. The thickness of the protective layer is set to 1/10 or less that of the sticking layer. The sticking agent used in the sticking layer is based on a water-soluble high-molecular compound, a water-retentive softening agent and a hydrophylic high-molecular compound or a hydrophobic rubbery substance. This sticking agent imparts no feeling of physical disorder when this poultice is stuck to the surface of the mucous membrane of the oral cavity for a long time and has no toxity to a human body.
BACKGROUND: B cells are essential for providing humoral protection against acute influenza A virus (IAV) infection. FcγRIIB, a regulator of antibody (Ab) production, influences immune responses during pathogen infections, but its specific impact on humoral protection and B cell-mediated responses against IAV remains unclear.
METHODS: To investigate FcγRIIB's role in host defense and B cell function during acute IAV infection, we generated mice with systemic FcγRIIB deficiency, functional impairment, and B cell-specific FcγRIIB deletion. We infected these mice with PR8 (H1N1) or Hkx31 (H3N2) IAVs and evaluated body weight preservation, survival rates, Ab production, viral neutralization, Ab affinity maturation, and germinal center B cell development.
RESULTS: Mice lacking FcγRIIB or with impaired function showed improved protection, preserved body weight, and increased survival rates during IAV infection. Notably, mice with haploinsufficient FcγRIIB function displayed protective effects. Selective deficiency of FcγRIIB in B cells led to enhanced Ab production, resulting in elevated IAV-specific Abs in the serum with superior viral neutralizing potency. However, the impact on the affinity maturation index of virus-specific Abs was modest. Accordingly, FcγRIIB-deficient B cells maintained normal germinal center B cell development during IAV infection, whereas wild-type mice exhibited delayed differentiation.
CONCLUSION: Our research underscores the pivotal role of FcγRIIB in host defense and B cell-mediated immunity during acute IAV infection. Additionally, our discoveries hold implications for antiviral treatments, particularly during the initial stages of IAV infection, aimed at enhancing the host's humoral immune response.
The study will include 100 patients who had covid pneumonia 3 months ago. If the inclusion / exclusion criteria are met, the patient is asked to sign an informed consent to participate in the study. Consenting patients are randomized to an intervention group or a control group. The control group (n = 50) will receive standard therapy, patients from the intervention group (n = 50) will be prescribed Taxifolin Aqua 30 mg per day in addition to standard therapy. Patients will be randomized to the control and main group using random number spreadsheets, assuming that the control and main groups will be homogeneous in the main demographic and clinical parameters. Patient monitoring will be carried out within 2 months from the date of inclusion. A follow-up visit is scheduled in 2 months. During the study, the patient will be regularly monitored for tolerance and safety of therapy with Taxifolin Aqua.
3 - Methyl - 7 - amino - cephalosporins of formula wherein R1 is hydrogen or an easily removable carboxyl-protecting group, are prepared by treating a corresponding 3-methyl-7-acylamino cephalosporin with at least 1 molar proportion of a solvent of formula R11-OH at 0-125 C. in the presence of at least 0À25 equivalent of an acid having a pKa below 3, R11 being hydrogen, methyl, ethyl or propyl and the acylating group in the starting cephalosporin having the formula or in which Q is hydrogen, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, cyano, nitro, hydroxy, chloro, bromo or fluoro Y is hydrogen or hydroxy X is oxygen or sulphur m is 0, 1 or 2 and n is 1, 2 or 3. The carboxyl-protecting group may be an easily removable esterifying group preferred starting materials are those wherein the acylating group is benzyl or phenoxymethyl. When the solvent R11-OH is water, an inert watermiscible organic co-solvent is preferably added to maintain the reactants and products in solution. Suitable acids are p-toluenesulphonic acid, methanesulphonic acid, trifluoroacetic acid, hydrochloric acid, phosphoric acid and sulphuric acid. The product may be obtained in the form of the salt of the acid used, e.g. pnitrobenzyl - 3 - methyl - 7 - amino - A3 - cephem- 4 - carboxylate p - toluenesulphonic acid salt monohydrate.
The present invention relates to facilitating detoxification and treatment of substance addiction. Accordingly, the present invention is broadly directed to a method for treating substance addiction subject comprising administering ketamine in an amount effective to facilitate detoxification or assist in overcoming substance addiction, or both. The present invention is broadly directed to transmucosal administration of ketamine. In a further embodiment, the present invention provides for parenteral administration of ketamine. Treatment with ketamine advantageously allows for patient self administration of the drug, which provides for management or treatment of a substance addiction on an outpatient basis. Moreover, ketamine administration in nasal sprays and inhalers are generally socially acceptable. In a specific example, a dedicated smoker was able to reduce her craving from three packs of ciga rettes a day.
BACKGROUND: Liver biopsy is the gold standard to evaluate hepatic fibrosis; however, it has many drawbacks, especially in patients with severe obesity. Noninvasive testing such as the FIB-4 score is increasingly being used as the initial screening tool to identify patients at risk for advanced fibrosis. The broader applicability of FIB-4 and the precision of its cutoff values remain uncertain in metabolic dysfunction-associated steatotic liver disease and patients with severe obesity. Our study explored the correlation between FIB-4 scores and intraoperative liver biopsy in patients with severe obesity undergoing bariatric surgery.
METHODS: A total of 632 patients with severe obesity underwent preoperative vibration-controlled transient elastography and intraoperative liver biopsy during bariatric surgery from January 2020 to August 2021. Variables collected included patient demographics, laboratory values, abdominal ultrasound, vibration-controlled transient elastography, and liver biopsy results. ANOVA 1-way test, χ 2 tests, and Fisher exact tests were used for quantitative and qualitative variables, respectively. The 95% CIs for the mean FIB-4 scores were used to generate surrogate cutoff values. The proposed FIB-4 cutoffs for F0-1, F2, F3, and F4 were 0.62 (CI: 0.59, 0.64), 0.88 (0.74, 1.01), 1.24 (0.94, 1.54), and 1.53 (0.82, 2.24), respectively. Area under the curve (AUC) methods were used to compare traditional to proposed cutoff values.
RESULTS: Applying the traditional FIB-4 cutoffs to approximate advanced fibrosis yielded an AUC of 0.5748. Use of the proposed FIB-4 cutoffs increased the AUC to 0.6899. The proposed FIB-4 cutoffs correctly identified 40 patients with biopsy-proven advanced fibrosis (F3-F4), all of which would have been missed using traditional cutoffs.
CONCLUSION: Our study revealed that the use of the currently accepted FIB-4 cutoffs as the screening modality for identifying patients with advanced fibrosis due to metabolic dysfunction-associated steatotic liver disease is insufficient and will result in missing patients with histologically confirmed advanced fibrosis. Use of the revised FIB-4 scores should be considered to diagnose patients with severe obesity at high risk of liver disease progression.
Acute myocardial infarction (AMI) is a life-threatening disease with a short course and a high mortality rate. However, it is still a great challenge to achieve the on-site diagnosis of this disease within minutes, meaning there is an urgent need to develop an efficient technology for realizing the rapid diagnosis and early warning of AMI in clinical emergencies. In this study, an ultrasensitive electrochemical aptasensor based on an extended-gate ion-sensitive field-effect transistor (EGISFET) was designed to achieve the quantitative assay of cardiac troponin I (cTnI), which is a highly sensitive and specific biomarker of AMI, within only 5 min. The EGISFET exhibits extremely high detection sensitivity due to its separated structure with a large sensing area and the surface-modified Prussian blue-gold nanoparticles (PB-AuNPs) composite, which serves as a signal magnifier and DNA loading platform for good electrocatalytic ability with a large specific area. Additionally, a target-induced strand-release strategy is proposed to shorten the recognition time of cTnI using a particular DNA strand. Under optimal conditions, the as-prepared aptasensor exhibits a wide linear range of 1-1000 pg/mL, an ultralow detection limit of 0.3 pg/mL, and reliable detection results in real serum samples. It is highly anticipated that this EGISFET-based aptasensor will have broad applications in the early warning and rapid diagnosis of AMI and other acute diseases in emergency treatment.
No dose reductions of DARZALEX are recommended. Consider withholding DARZALEX to allow recovery of blood cell counts in the event of myelosuppression [see Warnings and Precautions (5.3, 5.4)] . 

For information concerning drugs given in combination with DARZALEX, see manufacturer's prescribing information.

Infusion-Related Reactions

For infusion-related reactions of any grade/severity, immediately interrupt the DARZALEX infusion and manage symptoms. Management of infusion-related reactions may further require reduction in the rate of infusion, or treatment discontinuation of DARZALEX as outlined below [see Warnings and Precautions (5.1)] . 

  * Grade 1–2 (mild to moderate): Once reaction symptoms resolve, resume the infusion at no more than half the rate at which the reaction occurred. If the patient does not experience any further reaction symptoms, infusion rate escalation may resume at increments and intervals as clinically appropriate up to the maximum rate of 200 mL/hour (Table 6).
  * Grade 3 (severe): Once reaction symptoms resolve, consider restarting the infusion at no more than half the rate at which the reaction occurred. If the patient does not experience additional symptoms, resume infusion rate escalation at increments and intervals as outlined in Table 6. Repeat the procedure above in the event of recurrence of Grade 3 symptoms. Permanently discontinue DARZALEX upon the third occurrence of a Grade 3 or greater infusion-related reaction.
  * Grade 4 (life-threatening): Permanently discontinue DARZALEX.
Hyperlipidemia is one of the most important risk factors to cause atherosclerosis that ultimately triggers cardiovascular complications like myocardial infarction, ischemic stroke, peripheral vascular disease etc. These are considered as the leading cause of mortality and morbidity worldwide. Nigella sativa has both lipid lowering and anti-oxidant potentials. In this regard Nigella Sativa can be given with standard therapy to regulate blood lipids.

Aim of this study: This proposed study is therefore an effort to find out the safety and efficacy of Nigella Sativa in patient with hyperlipidemia.This study will be a single center study, utilizing a randomized, double-blind, placebo controlled trial. It will be conducted in the department of pharmacology, BSMMU in collaboration with the department of cardiology, BSMMU from the day of approval by the Institutional Review Board to June, 2024. The study will involve a total of Eighty four (84) patients attended in the outpatient department of cardiology, BSMMU, diagnosed as hyperlipidemia, with 42 of them receiving standard treatment along with a twice daily dose of 500mg of Nigella Sativa capsule for 8 weeks. The remaining 42 patients will undergo standard treatment along with a placebo over the same duration. The data collected will be analyzed through descriptive statistical techniques, offering a comprehensive summary of the results. In this study we will assess various sociodemographic characteristics of all the participants, including like age, sex, body mass index (BMI).In addition to these factors we will also evaluate their lipid profile, serum glutamic pyruvic transaminase (SGPT), serum creatinine level at baseline and after 8 weeks of interventions. Addition of Nigella Sativa with the conventional treatment of Statin could potentially reduce blood lipids in patients with hyperlipidemia.
Provided is a safe vaccine for mycoplasma infection with high therapeutic effect and a method for effectively treating mycoplasma infection. Also provid is an effective pseudo-mycoplasma particle and a pseudo-bacteria particle including general bacteria as a vaccine for mycoplasma infection disease. In this application, a pseudo-bacteria particle such as pseudo-mycoplasma particle etc. can be provided by making a liposome particle comprising the lipid antigen being specific to pathogenic bacteria such as mycoplasma etc. as the lipid component of liposome. By administrating the pseudo-mycoplasma particle, a strong immune activity in vivo can be induced, thus provides an excellent vaccine for preventing or treating the mycoplasma infection disease.
The invention provides a traditional Chinese medicine composition used for treating gynecologic diseases such as cervicitis, and a preparation method thereof. The composition is prepared from tree-of-heaven ailanthus bark, lightyellow sophora root, frankincense, borneol, and tree peony root-bark. The cervicitis-treating traditional Chinese medicine composition provided by the invention provides functions of heat clearing, dampness removing, morbid leucorrhea stopping, itching relieving, necrotic tissue removing, granulation promoting, astringing, and bleeding stopping. The medicine composition can be widely applied for treating gynecologic diseases caused by pathogens such as bacteria, fungi, protozoan, chlamydia, mycoplasma, and the like. Also, the medicine has an effect as a pH buffering agent. Through the regulation upon the vagina pH, a vagina self-cleaning function can be recovered.
BACKGROUND: Aberrations in blood phosphate (Pi) levels, whether presenting as hypo- or hyperphosphatemia, appear to be associated with clinical complications and adverse outcomes in patients admitted to an intensive care unit (ICU). However, the prevalence of Pi disorders and the association with subsequent factors and organ failures leading to death in ICU patients are poorly described. Despite endeavors to understand the etiology and treatment of low Pi levels from systematic reviews and meta-analyses, the literature lacks comprehensive guidance for managing hypophosphatemia. Hyperphosphatemia, on the other hand, appears to be associated with higher mortality among critically ill patients, yet its prevalence among ICU patients, particularly following phosphate repletion, remains unknown. The present study aims to investigate the prevalence of Pi abnormalities upon ICU admission and their incidence during the first week of ICU stay, the factors associated with Pi alterations, and the effect of phosphate repletion on the normalization of Pi levels, and its associations with clinical outcomes.
METHODS: This multicentre, prospective, non-interventional cohort study will include at least 1000 consecutive adult ICU patients (≥18 years) as part B of the GUTPHOS study. Sites are eligible if an anticipated minimal inclusion of 50 eligible patients during eight weeks from January 2024 until June 2024 and daily phosphate measurements during the first seven days of ICU stay are expected. All consecutive adult patients admitted to a participating ICU during the recruitment period, lasting up to eight weeks, or up to 120 patients if enrollment reaches that limit earlier, will be included. Study parameters include study site characteristics, patient demographics, daily assessment of Pi levels, Pi-related treatment, feeding details, renal replacement therapy details, the incidence of refeeding-associated hypophosphatemia and administered medication (during the first seven calendar days of ICU stay). There will be a follow-up period of a maximum of 90 days to document 28- and 90-day all-cause mortality as the primary outcome. Multiple logistic regression will be used to assess independent associations with mortality in addition to Receiver Operating Characteristics curves to identify cut-off Pi values associated with mortality and overcorrection. Linear mixed models will be conducted to assess Pi treatment effects. Subgroup analyses will be performed based on Pi abnormalities observed during ICU admission, categorized as normo-, hypo-, hyper-, or mixed, along with its severity (mild, moderate, or severe).
DISCUSSION: The GUTPHOS study will be the first multicentre, prospective observational cohort study to investigate the prevalence, management practices, and consequent outcomes associated with Pi abnormalities during the first week of ICU admission. Its results may bridge the current evidence gap in repletion protocols while establishing the groundwork for a subsequent randomized controlled trial.
CLINICAL TRIAL REGISTRY: NCT05909722.
The invention enables management of mammalian disease related to decreased energy production in the mitochondria, the powerhouse of the cell. The invention uses the combination of liposomal reduced glutathione and l-arginine to increase the ability weight loss in individuals with excess weight. The mechanism of weight loss appears to be related to improving the inefficient production of energy by the respiratory transport chain of mitochondria, the function of which are influenced positively by the availability of antioxidant nitric oxide in a non-oxidized environment. This invention enables weight loss in individuals who's inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production. The pathways related to inability to lose weight are also related to the phenomenon of the inability to metabolize fats, which results in insulin resistance and diabetes. The invention is useful for the management of the metabolic syndrome. The metabolic syndrome is actually a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well generally in the body is part of the benefit of the combination of liposomal reduced glutathione and l-arginine. In addition, the biochemical pathways stimulated by this invention can have a beneficial effect in individuals suffering from a variety of infectious diseases.
Group B will receive oral tramacet 2 tablets preoperatively and then 2 tablets every 6 hours for five days. ( or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). This group will also receive saline infusion at 4-6mls / hour for the duration of the hospital stay.